Peri-operative modulation of cellular immunity in patients with colorectal cancer
- 1 October 1993
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 94 (1) , 4-10
- https://doi.org/10.1111/j.1365-2249.1993.tb05968.x
Abstract
SUMMARY: The peri-operalive cellular immune response is depressed in patients with gastrointestinal cancer, a factor which may facilitate maligtiant dissemination. We have investigated the effects of perioperative rIL-2 and a combination of rlL-2 and interferon-alpha (IFN-α) on both peripheral blood lymphocyte function and number in patients undergoing surgical resection for colorectal cancer. Fifty-two patients were randomly allocated to either control, rIL-2 or rIL-2 with IFN-α treatment arms. In vitro studies were performed pre-operatively and on post-operative days I, 4, 7 and 10. Natural ikller (NK) and lymphokine-activated killer (LAK) cell function were profoundly depressed in control patients (P < 0·001; P < 0·001), an effect abrogated in both treatment groups; indeed NK function was augmented in the rIL-2 and IFN-α group on the first post-operative day in association with an increase in the percentage of cells expressing CD16 and CD56 (P < 0.01). Flow cytometric analysis of lymphocyte subsets in the control group was unremarkable, except for an early post-operative fall in numbers of lymphocytes. Treatment with either rIL-2 or rIL-2 and IFN-α produced an initial profound reduction in T lymphocyte numbers, followed by a ‘rebound’ lymphocytosis of activated CD3+ T cells, as demonstrated by a significant increase in co-expression of CD25, CD38, and CD45RO. No significant differences were observed between either of the treatment groups. Adjuvant immunotherapy affects peri-operative anti-tumour immune responses, and this may influence long term outcome in patients undergoing surgery for gastrointestinal cancer.Keywords
This publication has 36 references indexed in Scilit:
- Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignanciesThe Lancet, 1990
- Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon CarcinomaNew England Journal of Medicine, 1990
- Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection.The Journal of Experimental Medicine, 1987
- Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancerBritish Journal of Surgery, 1987
- Outcome of colorectal cancerBritish Journal of Surgery, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Occult hepatic metastases in colorectal carcinomaBritish Journal of Surgery, 1986
- Immune interferon: a pleiotropic lymphokine with multiple effectsImmunology Today, 1985
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982